posted
Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
Nov 1, 2007 09:00:22 (ET)
LOS ANGELES, Nov 01, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that William M. Caldwell, IV, its Chairman and Chief Executive Officer, will present at The Rodman & Renshaw Acumen BioFin 9th Annual Healthcare Conference in New York City on Monday, November 5th, 2007 at 11:15 AM Eastern Time. The conference will be held at The New York Palace Hotel, New York City. The Company's audio portion and slides of its presentation will also be webcast live and archived for future reference at http://www.wsw.com/webcast/rrshq12/cgxp.ob .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300 Steven S. Porter, 720-946-6440
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
This is picking up more on other boards M8. Holding strong.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
LOS ANGELES, Nov 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has appointed Jonathan H. Dinsmore, Ph.D. to the position of Senior Vice President - Regulatory and Clinical and Ivan Wolkind to the position of Senior Vice President - Finance, Administration & Chief Accounting Officer. Dr. Dinsmore was previously the company's Vice President and General Manager, while Mr. Wolkind was previously Vice President of Finance and Chief Accounting Officer.
"I am pleased to recognize the contributions of Jonathan and Ivan with expanded roles and responsibilities," said William M. Caldwell, IV, its Chairman and Chief Executive Officer. "Today, Advanced Cell Technology has positioned itself to become a leading participant in the field of regenerative medicine, helped by the contributions of these talented executives."
Dr. Jonathan H. Dinsmore was formerly responsible for all aspects of Mytogen's cell production operations, basic science program, and research and development efforts. He was also actively engaged in evaluating partnership opportunities and complimentary technologies. Prior to his position with Advanced Cell Technology and Mytogen, he directed both clinical and preclinical research programs at Diacrin and GenVec. Dr. Dinsmore has research and clinical experience in the development of therapeutic products to treat Parkinson's disease, Huntington's disease, epilepsy, stroke, spinal cord injury, chronic intractable pain, liver disease, and cardiovascular disease. Dr. Dinsmore received a B.S. in Biology from Boston College followed by a Ph.D. in Biology from Dartmouth College. Dr. Dinsmore was a Post-doctoral fellow at MIT from 1989 to 1992. His extensive accomplishments include numerous awarded and pending patents as well as diverse published studies on myoblast transplantation technology.
Mr. Wolkind joined the company in May 2005. Prior to joining Advanced Cell, he served as the Executive Vice President of Finance and Chief Financial Officer for Eyematic, a technology company providing software solutions for delivering animated content to cell phones. Between 1999 and July 2001, Mr. Wolkind was the Chief Financial Officer for eLease, a company providing software solutions and back end automation for the capital equipment leasing market. Prior to his appointment at eLease, Mr. Wolkind served as the Vice President of Finance for Ventro Corporation, where he was instrumental in the raising of capital in the company's initial public offering and subsequent debt offerings. Before his tenure at Ventro Corporation, Mr. Wolkind served as the Vice President of Finance at Onsale, Inc., a publicly traded Internet auction company. Prior to joining Onsale, he held key finance positions at two other companies after leaving KPMG, where he had worked in the financial services and banking audit group. Mr. Wolkind qualified as a Chartered Accountant in the United Kingdom.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Couple good recent PRs. Let's see if they can do anything. Chart says this could dip a bit more but 1 little candle says this is ready to turn.
cover one eye while reading this one so you miss the grammer mistake...
News for 'ACTC' - (Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology / Association of Rheumatology Health Professionals)
LOS ANGELES, Nov 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker, delivering the opening presentation at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.
The ACR Annual Meeting is the rheumatology industry's leading conference, with over 14,000 scientists and attendees expected. Dr. Lanza will be delivering a presentation titled "The Use of Embryonic Stem Cells in Regenerative Medicine."
During the presentation, Dr. Lanza is expected to discuss the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support. About Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies for RPE Program at Neuroscience 2007 Monday November 5, 10:59 am ET GMP-compliant RPE cells show significant rescue of vision in the Royal College of Surgeons (RCS) Rat
LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC) and the Casey Eye Institute at Oregon Health & Science University initiated a significant collaboration over a year ago that has culminated in a robust study of dosage and efficacy of the GMP-compliant RPE cells. Today at Neuroscience 2007, these researchers are presenting the results of the study using ACT’s embryonic stem cell derived RPE cells in the RCS Rat, a well validated animal model of retinal disease. The RPE cells were manufactured under GMP compliant conditions (21CFR211) at the company’s facility in Worcester, MA. The RPE cells have been thoroughly characterized and cryo-preserved by the company and were shipped to researchers at OHSU for transplantation. The transplanted rats were given a range of doses of the RPE cells and monitored and evaluated at multiple time points. The results of the study showed that the RPE cells demonstrated a statistically significant therapeutic effect compared to controls with a maximum efficacious effect at a medium dose level. Histological assessment showed integration of the human RPE cells into the rodent’s RPE layer without migration into the retina. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing GMP-compliant human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like Age-related macular degeneration (AMD), where RPE function is compromised. Advanced Cell Technology plans to present this data to the FDA when it files an IND for the RPE therapy. ADVERTISEMENT
“We are excited by the results of this study which demonstrated the efficacy of our RPE cells in an animal model,” said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. “The data generated by our ongoing collaboration with OHSU represents another milestone in bringing our stem cell therapies from the laboratory to the clinic and ultimately to patients in need of treatment.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
need volume need volume need volume need volume
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
CORRECTING and REPLACING Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology / Association of Rheumatology Health Professionals
Nov 6, 2007 13:47:31 (ET)
LOS ANGELES, Nov 06, 2007 (BUSINESS WIRE) -- First graph, first sentence should read: Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston. (sted Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker, delivering the opening presentation at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.)
The corrected release reads:
ADVANCED CELL TECHNOLOGY'S CHIEF SCIENTIFIC OFFICER FEATURED SPEAKER AT AMERICAN COLLEGE OF RHEUMATOLOGY / ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS
Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.
The ACR Annual Meeting is the rheumatology industry's leading conference, with over 14,000 scientists and attendees expected. Dr. Lanza will be delivering a presentation titled "The Use of Embryonic Stem Cells in Regenerative Medicine."
During the presentation, Dr. Lanza is expected to discuss the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support. About Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
You think after all that effort they would correct something so simple.
If they draw in the institutional buying it'll be A okay with me!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
A little early morning action. Just a pinch, but usually doesn't wake up 'till around lunch time.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
ADVANCED CELL TECHNOLOGY, INC. 1201 Harbor Bay Parkway Alameda, CA 94502
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS DECEMBER [28], 2007
To Our Stockholders:
An Annual Meeting of Stockholders of Advanced Cell Technology, Inc., a Delaware corporation (the "Company"), will be held on [Wednesday], December [28], 2007 at 10:00 a.m., local time, at the offices of Pierce Atwood LLP, One Monument Square, Portland, Maine 04101, for the following purposes:
1. To elect five (5) members to our Board of Directors to serve a one-year term and until their respective successors are duly elected and qualified;
2. To amend the Company's 2005 Stock Incentive Plan (the "2005 Stock Plan") to increase the number of shares issuable thereunder by 25,000,000 shares (on a pre-reverse split basis); and
3. To consider and approve an Amended and Restated Certificate of Incorporation of the Company (the "Restated Certificate of Incorporation"), which amends and restates the Company's existing Certificate of Incorporation to effect a reverse split of the Company's outstanding shares of common stock, par value $.001 per share ("Common Stock"), at a ratio in the range from one-for-two to one-for-ten at any time before May 1, 2008.
4. To transact such other business as may properly come before the meeting or any adjournments thereof.
That splains the early action, as little as it was. LOL. Might get a nice dip from this and then who knows what.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
okay. I'm down to losing 60 shares long term. lol. where's my dip?
hurry up already!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- If your not on the edge of ur seat, sell it! Everything posted is my opinion! Posts: 992 | From: H-town | Registered: Nov 2006
| IP: Logged |
posted
see ya at the bottom. 1:10 or 1:2? imo the 25m will hit all at once sending this to the dog house. These guys lost their common sense imo. They only need to slow things down a little and keep hitting up through the administration for financing. I don't mind the dilution, I don't want the RS!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
intraday looks pretty good. If they had the right news (as in anything else duh!) this could really pop. If it weren't going down...
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
quote:Originally posted by IMAKEMONEY: BUYING BUYING BUYING,LOL,POP!!!
DAYTRADERS!! PHLEEEEEWY!!!
D
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
yah. I though .20 or so would be a good bounce. I was waiting it out though to see if it would drop lower. We'll see.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
My server changed hands - i was out from before lunch and most of the afternoon! grrrr
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology's Chief Executive Officer Scheduled to Be Interviewed By Bloomberg Television Tonight
Nov 20, 2007 15:46:04 (ET)
LOS ANGELES, Nov 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that William M. Caldwell, IV, the company's Chief Executive Officer is scheduled to be interviewed today by Bloomberg Television at 6:15 p.m. eastern time. Mr. Caldwell is expected to discuss the Company's Retinal Program, as well as other corporate developments and issues surrounding the stem cell industry.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
quote:Originally posted by IMAKEMONEY: HMM, NEWS COMING?????
you da man IMAKE
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Razz]](tongue.gif)
![[Eek!]](eek.gif)
![[Wink]](wink.gif)
